The 12th Annual BIO CEO & Investor Conference
An International Biotechnology Investor Conference Featuring Established & Emerging Public Companies
The 12th Annual BIO CEO & Investor Conference in 2010 was a huge success! So, don't miss the opportunities at the
|
The BIO CEO & Investor Conference is the largest investor conference focused on publicly traded biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities.
Our therapeutic workshops feature the latest information on pipeline innovation, and no other investor conference offers as many sessions involving MDs, CSOs, and industry analysts.
BIO One-on-One Partnering also provides an opportunity to arrange meetings between investors; companies; and industry BD, licensing and therapeutic franchise heads.
| Alger Boyer | Managing Director, Equities Group | Rodman & Renshaw, LLC |
| Benjamin R. Bowen, Ph.D. | Managing Director, Investment Banking | Rodman & Renshaw, LLC |
| Ron Cohen, M.D. | President & CEO | Acorda Therapeutics |
| J. Donald deBethizy, Ph.D. | President & CEO | Targacept |
| David Farhadi, M.D. | Vice President, Senior Analyst/Co-Portfolio Manager | Fred Alger Management, Inc. |
| Howard Furst, M.D. | Partner | Deerfield Management |
| Cory W. Kasimov | Vice President | J.P Morgan |
| David Kroin | Managing Director | Great Point Partners, LLC |
| Kelly Lisbakken | Vice President, Investment Banking | Wedbush PacGrow Life Sciences |
| Mark Schoenebaum, M.D. | Managing Director & Senior Biotechnology Analyst | Deutsche Bank AG |
| Chris Swindle | Managing Director | Wedbush PacGrow Life Sciences |
For more information, please contact BIO CEO customer service:
Email: biopartnering@bio.org
Phone: 866.356.5155, +1.202.962.6666
| BIO CEO Attracts a Focused Audience of Decision Makers | |
|